Th17 Cells and the IL-23 Axis
Th17 cells are not one lineage — they are two, and the cytokine that separates them is IL-23. TGF-β plus IL-6 starts the programme; IL-1β lowers the threshold; but it is IL-23, acting on cells that already carry IL-23R, that converts a transient, IL-10-producing, tissue-tolerant Th17 cell into the GM-CSF-producing pathogenic one that drives autoimmunity. The same STAT3 and RORγt module runs both. That single fact explains why anti-IL-23p19 antibodies work in psoriasis while direct IL-17 blockade fails in Crohn's disease — and why TGF-β without IL-6 gives you a Foxp3 regulatory cell instead. Click any protein for the matching Assay Genie In Vivo antibody or ELISA kit.
Differentiation and pathogenicity are two different decisions. The first is made in the lymph node: a dendritic cell presenting antigen alongside IL-6 and TGF-β1 pushes a naive CD4 cell towards RORγt. IL-1β, through IL-1R1 and MyD88–NF-κB, lowers the activation threshold and makes the commitment faster and more robust. The second decision comes later, in the tissue, and belongs to IL-23 — the heterodimer of IL-23p19 and the p40 chain it shares with IL-12. IL-23 cannot act on a naive cell at all, because IL-23R is only induced after the STAT3 programme has started. That ordering is the whole architecture of the axis: IL-6 and TGF-β open the door, IL-23 decides what walks through it.
One STAT, two outcomes. IL-6Rα, IL-23R and IL-12Rβ1 all converge on JAK2 and TYK2 and therefore on STAT3. STAT3 induces RORγt, sustains AHR, and drives IRF4 — and it also induces SOCS3, which shuts JAK2 down again. The strength and duration of the STAT3 signal, not its identity, is what separates a self-limiting response from a chronic one. RUNX1 co-operates with RORγt at the Il17a locus; AHR, activated by dietary and microbial ligands, biases output towards IL-22; and TCR signal strength, read out through IRF4, sets how much of the programme is written at all. A note on specificity: the RUNX1 antibody linked here is pan-RUNX1/2/3 and does not discriminate between family members.
The reciprocal branch is the same signal minus one cytokine. TGF-β1 on its own drives Foxp3 and a regulatory phenotype; add IL-6 and you get RORγt instead. RORγt and Foxp3 antagonise each other directly, and cells expressing both exist as an unstable intermediate. This is why depleting CD25+ regulatory cells in a model reliably amplifies a Th17 phenotype, and why IL-10 — produced by non-pathogenic Th17 cells themselves as well as by Tregs — is the cytokine whose loss converts a tolerogenic response into a destructive one.
The output is a tissue programme, not a killing programme. IL-17A and IL-17F signal through IL-17RA and TRAF6 in epithelium and stroma to make CXCL1 and G-CSF, which recruit and expand CD11b+ neutrophils, and CCL20, which pulls in more CCR6+ Th17 cells — a self-reinforcing loop. IL-22 acts only on epithelium and drives repair and MUC2 production rather than inflammation, which is why blocking it can worsen barrier disease. GM-CSF is the effector most tightly tied to pathogenicity in CNS and joint models, and IL-21 feeds back onto STAT3 as an autocrine amplifier. The In Vivo tie-in: the functional-grade layer here sits at the edges of the axis rather than its centre — anti-IL-1β and anti-GM-CSF to remove the two cytokines that most change severity, anti-CD4 to establish dependence on the lineage at all, anti-CD25 to strip the regulatory brake, anti-IL-10 to test whether a response is being held tolerogenic, and anti-CD11b to ask whether the damage is actually neutrophil-mediated. The IL-6, IL-23 and IL-17 nodes themselves are read with ELISA rather than blocked, and the map says so rather than padding the In Vivo layer with links that do not exist. For research use only; not for use in diagnostic or therapeutic procedures.
Every protein node links to a product — In Vivo antibody, ELISA kit or research antibody.